This study compared the effect of robotic cholecystectomy (RC) with a new port placement versus that of laparoscopic cholecystectomy (LC) on surgical pain and postoperative complications. We prospectively collected medical data from 100 patients who underwent cholecystectomy (RC = 50, LC = 50) from March 2017 to January 2019. In the RC group, ports were positioned in the left-lower, mid-lower, and umbilical areas. In the LC group, ports were placed in the xiphoid, right-upper, and umbilical areas. Patient characteristics were similar between the two groups. Pain levels at 2, 4, and 8 h were significantly lower in the RC group than in the LC group (p = 0.04, 0.02, and 0.02, respectively). The LC group received more analgesics after surgery (RC = 0.3 ± 0.5 vs. LC = 0.7 ± 0.9, p = 0.03). However, the total medical cost was significantly higher in the RC group (RC = 7355.2 ± 1270.9 USD vs. LC = 4814.8 ± 1572.5 USD, p < 0.01). Mean operative time, length of hospital stay, and postoperative complications were not significantly different between the two groups. Regardless of the surgical procedure, postoperative complications were similar. RC with the new port placement can be recommended for patients who are more concerned about postoperative pain, incision, and hospital stay than surgical cost.
1 January 2021 in Annals of Surgical Treatment and Research
With the increase in the frequency of robotic surgery, complications have also increased, including trocar site hernias, which rarely occur at the 8-mm port site after robotic cholecystectomy using the da Vinci Xi system. A 37-year-old woman was diagnosed with cholecystitis on abdominal...
1 January 2014 in Journal of Korean Medical Science
Several studies have suggested that a positive lymphocyte cross-matching (XM) is associated with low graft survival rates and a high prevalence of acute rejection after adult living donor liver transplantations (ALDLTs) using a small-for-size graft. However, there is still no consensus on preoperative desensitization. We adopted the desensitization protocol from ABO-incompatible LDLT. We performed desensitization for the selected patients according to the degree of T lymphocyte cross-match titer, model for end-stage liver disease (MELD) score, and graft liver volume. We retrospectively evaluated 230 consecutive ALDLT recipients for 5 yr. Eleven recipients (4.8%) showed a positive XM. Among them, five patients with the high titer (> 1:16) by antihuman globulin-augmented method (T-AHG) and one with a low titer but a high MELD score of 36 were selected for desensitization: rituximab injection and plasmapheresis before the transplantation. There were no major side effects of desensitization. Four of the patients showed successful depletion of the T-AHG titer. There was no mortality and hyperacute rejection in lymphocyte XM-positive patients, showing no significant difference in survival outcome between two groups (P=1.000). In conclusion, this desensitization protocol for the selected recipients considering the degree of T lymphocyte cross-match titer, MELD score, and graft liver volume is feasible and safe.